Drug Trial Radar · NCT04467905
ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Nov 19, 2020
Primary completion
Aug 3, 2023
Study completion Aug 10, 2023
Sponsor
- Lead sponsor
- Milestone Pharmaceuticals Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Montreal Health Innovations Coordinating Center (MHICC); JSS Medical Research Inc.
- First posted
- Jul 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Many patients with atrial fibrillation (AF) experience persistent tachycardia with episodes of rapid ventricular rate despite chronic treatment to reduce ventricular rate. The objectives of this study were to demonstrate the superiority of a nasal spray of etripamil over placebo in reducing ventricular rate in patients with AF; and to evaluate the safety and efficacy of etripamil nasal spray in participants with AF.
Conditions
- Atrial Fibrillation
Interventions
EtripamilDrug
The formulation of etripamil nasal spray consists of MSP-2017 (etripamil), water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg.
PlaceboDrug
The formulation of placebo nasal spray consists of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration.Time frame: 60 minutes post drug administration
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
QEII HSC - Nova Scotia Health Authority
Halifax, Nova Scotia, Canada
Hamilton Health Science
Hamilton, Ontario, Canada
PACE (Partners in Advanced Cardiac Evaluation)
Newmarket, Ontario, Canada
Ottawa Hospital General & Civic Campus Research Institute
Ottawa, Ontario, Canada
Institut de Cardiologie de Montreal
Montreal, Quebec, Canada
CHU Montréal
Montreal, Quebec, Canada
CIUSSS du Nord-de-l'Île-de-Montréal - Hôpital du Sacré-Cœur
Montreal, Quebec, Canada
CISSS Bas-Saint-Laurent / Hôpital de Rimouski
Rimouski, Quebec, Canada
CISSS des Laurentides / Unité de recherche clinique
Saint-Jérôme, Quebec, Canada
CIUSSS de l'Estrie - CHU
Sherbrooke, Quebec, Canada
CISSS de Lanaudière - Hôpital Pierre-Le Gardeur
Terrebonne, Quebec, Canada
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
Jeroen Bosch Ziekenhuis Rijnstate Ziekenhuis
Arnhem, Netherlands
Slingeland Ziekenhuis
Doetinchem, Netherlands
Treant Zorggroep
Emmen, Netherlands
Elkerliek Ziekenhuis
Helmond, Netherlands
Franciscus Gasthuis
Rotterdam, Netherlands
Gelre Ziekenhuizen
Zutphen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.